JP2021524439A5 - - Google Patents

Info

Publication number
JP2021524439A5
JP2021524439A5 JP2020564427A JP2020564427A JP2021524439A5 JP 2021524439 A5 JP2021524439 A5 JP 2021524439A5 JP 2020564427 A JP2020564427 A JP 2020564427A JP 2020564427 A JP2020564427 A JP 2020564427A JP 2021524439 A5 JP2021524439 A5 JP 2021524439A5
Authority
JP
Japan
Prior art keywords
alkyl
groups
substituted
hydrogen
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020564427A
Other languages
English (en)
Japanese (ja)
Other versions
JP7508375B2 (ja
JP2021524439A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/032292 external-priority patent/WO2019222269A1/en
Publication of JP2021524439A publication Critical patent/JP2021524439A/ja
Publication of JP2021524439A5 publication Critical patent/JP2021524439A5/ja
Priority to JP2024098452A priority Critical patent/JP2024125338A/ja
Application granted granted Critical
Publication of JP7508375B2 publication Critical patent/JP7508375B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020564427A 2018-05-14 2019-05-14 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド Active JP7508375B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024098452A JP2024125338A (ja) 2018-05-14 2024-06-19 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671047P 2018-05-14 2018-05-14
US62/671,047 2018-05-14
PCT/US2019/032292 WO2019222269A1 (en) 2018-05-14 2019-05-14 Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024098452A Division JP2024125338A (ja) 2018-05-14 2024-06-19 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド

Publications (3)

Publication Number Publication Date
JP2021524439A JP2021524439A (ja) 2021-09-13
JP2021524439A5 true JP2021524439A5 (cg-RX-API-DMAC7.html) 2022-05-20
JP7508375B2 JP7508375B2 (ja) 2024-07-01

Family

ID=67002352

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020564427A Active JP7508375B2 (ja) 2018-05-14 2019-05-14 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド
JP2024098452A Pending JP2024125338A (ja) 2018-05-14 2024-06-19 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024098452A Pending JP2024125338A (ja) 2018-05-14 2024-06-19 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド

Country Status (18)

Country Link
US (2) US11827664B2 (cg-RX-API-DMAC7.html)
EP (1) EP3794009A1 (cg-RX-API-DMAC7.html)
JP (2) JP7508375B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210021457A (cg-RX-API-DMAC7.html)
CN (2) CN119285591A (cg-RX-API-DMAC7.html)
AU (2) AU2019271126B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020023277A2 (cg-RX-API-DMAC7.html)
CA (1) CA3100333A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002957A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020015380A2 (cg-RX-API-DMAC7.html)
EA (1) EA202092727A1 (cg-RX-API-DMAC7.html)
IL (2) IL309891B2 (cg-RX-API-DMAC7.html)
MX (2) MX2025007723A (cg-RX-API-DMAC7.html)
PE (1) PE20211917A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551941A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202011311YA (cg-RX-API-DMAC7.html)
UA (1) UA130486C2 (cg-RX-API-DMAC7.html)
WO (1) WO2019222269A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014019704B1 (pt) 2012-02-09 2022-05-31 University Of Kansas Compostos inibidores de hsp90 c-terminais, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou prevenção de um distúrbio neurodegenerativo
MX2025007723A (es) 2018-05-14 2025-08-01 Reata Pharmaceuticals Inc Biarilamidas con grupos de azucar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteina de choque de calor
JP6899975B2 (ja) 2018-05-14 2021-07-07 ギリアード サイエンシーズ, インコーポレイテッド Mcl−1阻害剤
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
CA3294692A1 (en) 2019-11-26 2026-03-02 Gilead Sciences, Inc. Processes and intermediates for preparing mcl1 inhibitors
US12202782B2 (en) 2020-11-19 2025-01-21 Gilead Sciences, Inc. Processes and intermediates for preparing MCL1 inhibitors
US20230138729A1 (en) * 2021-09-13 2023-05-04 Rubedo Life Sciences, Inc. Coumarin Derivatives of Sugar Analogs and Uses Thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0547145A1 (en) 1990-09-07 1993-06-23 Schering Corporation Antiviral 2(1h)-quinolinone compounds
DE19512886A1 (de) 1995-04-06 1996-10-10 Bayer Ag Substituierte Cycloalkene
FR2792320B1 (fr) 1999-04-19 2003-05-09 Hoechst Marion Roussel Inc Nouveaux amides aromatiques substitues par un ribose, leur procede de preparation et leur application comme medicaments
WO2002044192A1 (en) 2000-11-30 2002-06-06 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
JP4263095B2 (ja) 2001-09-21 2009-05-13 ノバルティス アクチエンゲゼルシャフト Aceおよびnepの両阻害剤としてのピラン誘導体
US7208630B2 (en) 2004-10-27 2007-04-24 University Of Kansas Heat shock protein 90 inhibitors
US7622451B2 (en) 2004-11-03 2009-11-24 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
AU2005301957B2 (en) 2004-11-03 2012-02-23 Department Of Health And Human Services Novobiocin analogues as anticancer agents
US8212012B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues having modified sugar moieties
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
US8212011B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues
JP5175191B2 (ja) 2005-08-30 2013-04-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グリコピラノシル置換ベンジルベンゼン誘導体、該化合物を含有する医薬品及びその使用と製造方法
EP2131656A4 (en) 2006-11-15 2011-12-07 Forest Lab Holdings Ltd phthalazine
DE102007002715A1 (de) * 2007-01-18 2008-07-24 Merck Patent Gmbh Triazolderivat
EA019103B1 (ru) 2007-03-20 2014-01-30 Кьюрис, Инк. Конденсированный аминопиридин в качестве ингибиторов hsp90
US7960353B2 (en) 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
WO2009097578A1 (en) 2008-02-01 2009-08-06 Takeda Pharmaceutical Company Limited Oxim derivatives as hsp90 inhibitors
FR2928645A1 (fr) 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
WO2010014617A1 (en) 2008-07-28 2010-02-04 University Of Kansas Heat shock protein 90 inhibitor dosing methods
JP5766617B2 (ja) 2009-02-20 2015-08-19 ユニバーシティ・オブ・カンザス 修飾された糖部分を有するノボビオシン類似体
US20110082098A1 (en) 2009-09-30 2011-04-07 University Of Kansas Novobiocin analogues and treatment of polycystic kidney disease
TW201216957A (en) 2010-07-13 2012-05-01 Dainippon Sumitomo Pharma Co Biarylamide derivative or a pharmaceutically acceptable salt thereof
MX354215B (es) 2011-04-05 2018-02-19 Sloan Kettering Inst Cancer Res Inhibidores de la proteina 90 de choque termico (hsp90).
US9056104B2 (en) 2011-05-20 2015-06-16 The University Of Kansas Dynamic inhibitors of heat shock protein 90
WO2013112548A1 (en) 2012-01-23 2013-08-01 University Of South Florida Gamma-aapeptides with potent and broad-spectrum antimicrobial activity
BR112014019704B1 (pt) 2012-02-09 2022-05-31 University Of Kansas Compostos inibidores de hsp90 c-terminais, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou prevenção de um distúrbio neurodegenerativo
US9422230B2 (en) 2013-05-09 2016-08-23 Council Of Scientific And Industrial Research Process for the preparation of an anticonvulsant agent pregabalin hydrochloride
EP3066072B1 (en) 2013-11-07 2021-11-03 The University of Kansas Biphenylamide derivative hsp90 inhibitors
WO2015070238A2 (en) 2013-11-11 2015-05-14 The University Of Kansas Coumarin based hsp90 inhibitors with urea and ether substituents
EP3154964B1 (en) 2014-06-13 2023-04-05 The University of Kansas Triazole modified coumarin and biphenyl amide-based hsp90 inhibitors
CA3289739A1 (en) 2014-06-24 2025-11-29 The University Of Kansas Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers
MX2025007723A (es) 2018-05-14 2025-08-01 Reata Pharmaceuticals Inc Biarilamidas con grupos de azucar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteina de choque de calor

Similar Documents

Publication Publication Date Title
JP2017521496A5 (cg-RX-API-DMAC7.html)
JP2021521200A5 (cg-RX-API-DMAC7.html)
JP2024509981A5 (cg-RX-API-DMAC7.html)
JP2024001048A5 (cg-RX-API-DMAC7.html)
EP3672591B1 (en) Synergistic antitumor effect of bcl-2 inhibitor combined with rituximab and/or bendamustine or bcl-2 inhibitor combined with chop
JP2025060958A (ja) インテグリン標的化リガンドとその使用
JP7808963B2 (ja) HIF-2アルファ(EPAS1)の発現を阻害するためのRNAi剤、その組成物及び使用方法
JP2017019854A (ja) 自己免疫性疾患の処置剤
JP2023505434A5 (cg-RX-API-DMAC7.html)
US20140179919A1 (en) Compounds, compositions, methods of synthesis, and methods of treatment
JP2022536993A5 (cg-RX-API-DMAC7.html)
JP2022507404A5 (cg-RX-API-DMAC7.html)
JP2026501616A (ja) N-メチレンアミドリンカーを含有する抗体-薬物複合体
JP2007529426A5 (cg-RX-API-DMAC7.html)
JP2023507402A5 (cg-RX-API-DMAC7.html)
JP2021527650A5 (cg-RX-API-DMAC7.html)
JP2022510374A5 (cg-RX-API-DMAC7.html)
JP2023510865A5 (cg-RX-API-DMAC7.html)
JP2024509625A5 (cg-RX-API-DMAC7.html)
WO2002030872A1 (en) Novel aliphatic compounds, process for their preparation and their usage
JP2022521474A5 (cg-RX-API-DMAC7.html)
RU2732417C1 (ru) Производные фенотиазина и способы их применения
JP2021533115A5 (cg-RX-API-DMAC7.html)
AU2020103878A4 (en) Compounds and methods for treating influenza
JP7506660B2 (ja) デンドリマー製剤